<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00933985</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2011-01936</org_study_id>
    <secondary_id>NCI-2011-01936</secondary_id>
    <secondary_id>COG-ADVL0816</secondary_id>
    <secondary_id>CDR0000647160</secondary_id>
    <secondary_id>ADVL0816</secondary_id>
    <secondary_id>ADVL0816</secondary_id>
    <secondary_id>U01CA097452</secondary_id>
    <nct_id>NCT00933985</nct_id>
  </id_info>
  <brief_title>Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia</brief_title>
  <official_title>A Phase I Study of Obatoclax (Pan Anti-Apoptotic BCL-2 Family Small Molecule Inhibitor), in Combination With Vincristine/Doxorubicin/Dexrazoxane, in Children With Relapsed/Refractory Solid Tumors or Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects and best dose of obatoclax mesylate when&#xD;
      given together with vincristine sulfate, doxorubicin hydrochloride, and dexrazoxane&#xD;
      hydrochloride in treating young patients with relapsed or refractory solid tumors, lymphoma,&#xD;
      or leukemia. Obatoclax mesylate may stop the growth of cancer cells by blocking some of the&#xD;
      proteins needed for cell growth and causing the cells to self-destruct. Drugs used in&#xD;
      chemotherapy, such as vincristine sulfate, doxorubicin hydrochloride, and dexrazoxane&#xD;
      hydrochloride, work in different ways to stop the growth of cancer cells, either by killing&#xD;
      the cells or by stopping them from dividing. Giving obatoclax mesylate together with&#xD;
      combination chemotherapy may kill more cancer cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To estimate the maximum tolerated dose (MTD) and/or recommended Phase II dose of obatoclax&#xD;
      (obatoclax mesylate) administered as a single agent on day 1 and in combination with&#xD;
      vincristine ( vincristine sulfate), doxorubicin (doxorubicin hydrochloride), and dexrazoxane&#xD;
      (dexrazoxane hydrochloride) at day 8 in children with refractory solid tumors.&#xD;
&#xD;
      II. To define and describe the toxicities of obatoclax administered on this schedule.&#xD;
&#xD;
      III. To characterize the pharmacokinetics of obatoclax in children with refractory solid&#xD;
      tumors or relapsed leukemia.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To preliminarily define the antitumor activity of obatoclax in children with refractory or&#xD;
      relapsed solid tumors and leukemias within the confines of a Phase I study.&#xD;
&#xD;
      II. To preliminarily assess leukemic blast characteristics associated with obatoclax&#xD;
      activity.&#xD;
&#xD;
      III. To preliminarily assess the biological activity of obatoclax by investigating effects on&#xD;
      cell death regulatory pathways.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of obatoclax mesylate.&#xD;
&#xD;
      STRATUM 1 (dose-escalation): Patients receive obatoclax mesylate intravenously (IV) over 3&#xD;
      hours on days 1 and 8 and vincristine sulfate IV, doxorubicin hydrochloride IV, and&#xD;
      dexrazoxane hydrochloride IV on day 8 of course 1 (28 days). Drugs are administered on day 1&#xD;
      of subsequent courses and repeat every 21 days for up to 1 year in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      STRATUM 2: Patients receive obatoclax mesylate (at starting dose in stratum 1), vincristine&#xD;
      sulfate, doxorubicin hydrochloride, and dexrazoxane hydrochloride as in stratum 1.&#xD;
&#xD;
      STRATUM 3: Patients receive obatoclax mesylate (at the MTD determined in stratum 1),&#xD;
      vincristine sulfate, doxorubicin hydrochloride, and dexrazoxane hydrochloride as in stratum&#xD;
      1.&#xD;
&#xD;
      After completion of study therapy, patients are followed up for 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum-tolerated dose of obatoclax mesylate in combination with vincristine sulfate, doxorubicin hydrochloride, and dexrazoxane hydrochloride, defined as the maximum dose at which fewer than one-third of patients experience dose limiting toxicity</measure>
    <time_frame>28 days</time_frame>
    <description>Will be assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events characterized by grade, relationship to study therapy, and prior experience, assessed by NCI CTCAE v4.0</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Descriptive summary of all toxicities will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease response assessed using Response Evaluation Criteria in Solid Tumors</measure>
    <time_frame>Up to 30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Acute Leukemias of Ambiguous Lineage</condition>
  <condition>Acute Undifferentiated Leukemia</condition>
  <condition>Angioimmunoblastic T-cell Lymphoma</condition>
  <condition>Blastic Phase Chronic Myelogenous Leukemia</condition>
  <condition>Childhood Burkitt Lymphoma</condition>
  <condition>Childhood Chronic Myelogenous Leukemia</condition>
  <condition>Childhood Diffuse Large Cell Lymphoma</condition>
  <condition>Childhood Immunoblastic Large Cell Lymphoma</condition>
  <condition>Childhood Nasal Type Extranodal NK/T-cell Lymphoma</condition>
  <condition>Cutaneous B-cell Non-Hodgkin Lymphoma</condition>
  <condition>Hepatosplenic T-cell Lymphoma</condition>
  <condition>Intraocular Lymphoma</condition>
  <condition>Noncutaneous Extranodal Lymphoma</condition>
  <condition>Peripheral T-cell Lymphoma</condition>
  <condition>Recurrent Childhood Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Childhood Acute Myeloid Leukemia</condition>
  <condition>Recurrent Childhood Anaplastic Large Cell Lymphoma</condition>
  <condition>Recurrent Childhood Grade III Lymphomatoid Granulomatosis</condition>
  <condition>Recurrent Childhood Large Cell Lymphoma</condition>
  <condition>Recurrent Childhood Lymphoblastic Lymphoma</condition>
  <condition>Recurrent Childhood Small Noncleaved Cell Lymphoma</condition>
  <condition>Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma</condition>
  <condition>Recurrent Mycosis Fungoides/Sezary Syndrome</condition>
  <condition>Recurrent/Refractory Childhood Hodgkin Lymphoma</condition>
  <condition>Refractory Chronic Lymphocytic Leukemia</condition>
  <condition>Refractory Hairy Cell Leukemia</condition>
  <condition>Relapsing Chronic Myelogenous Leukemia</condition>
  <condition>Small Intestine Lymphoma</condition>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Treatment (obatoclax, vincristine, doxorubicin, dexrazoxane)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>STRATUM 1 (dose-escalation): Patients receive obatoclax mesylate IV over 3 hours on days 1 and 8 and vincristine sulfate IV, doxorubicin hydrochloride IV, and dexrazoxane hydrochloride IV on day 8 of course 1 (28 days). Drugs are administered on day 1 of subsequent courses and repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity.&#xD;
STRATUM 2: Patients receive obatoclax mesylate (at starting dose in stratum 1), vincristine sulfate, doxorubicin hydrochloride, and dexrazoxane hydrochloride as in stratum 1.&#xD;
STRATUM 3: Patients receive obatoclax mesylate (at the MTD determined in stratum 1), vincristine sulfate, doxorubicin hydrochloride, and dexrazoxane hydrochloride as in stratum 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexrazoxane hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (obatoclax, vincristine, doxorubicin, dexrazoxane)</arm_group_label>
    <other_name>Cardioxane</other_name>
    <other_name>Savene</other_name>
    <other_name>Totect</other_name>
    <other_name>Zinecard</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (obatoclax, vincristine, doxorubicin, dexrazoxane)</arm_group_label>
    <other_name>ADM</other_name>
    <other_name>ADR</other_name>
    <other_name>Adria</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>obatoclax mesylate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (obatoclax, vincristine, doxorubicin, dexrazoxane)</arm_group_label>
    <other_name>GX15-070MS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liposomal vincristine sulfate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (obatoclax, vincristine, doxorubicin, dexrazoxane)</arm_group_label>
    <other_name>liposomal vincristine</other_name>
    <other_name>Marqibo</other_name>
    <other_name>vincristine liposomal</other_name>
    <other_name>vincristine sulfate liposome injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (obatoclax, vincristine, doxorubicin, dexrazoxane)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (obatoclax, vincristine, doxorubicin, dexrazoxane)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Stratum 1 (solid tumors, including lymphomas): patients must have had histologic&#xD;
             verification of malignancy at original diagnosis or relapse; patients with recurrent&#xD;
             or refractory solid tumors are eligible, excluding primary central nervous system&#xD;
             (CNS) tumors or patients with known CNS metastases&#xD;
&#xD;
          -  Stratum 2 (mixed-lineage leukemia [MLL] + leukemia): patients with recurrent or&#xD;
             refractory MLL+ leukemia are eligible excluding those patients with symptomatic CNS&#xD;
             leukemia, CNS chloromas, or leptomeningeal leukemic involvement&#xD;
&#xD;
          -  Stratum 3 (other leukemias): patients with non-MLL+ recurrent or refractory leukemia&#xD;
             (acute lymphoblastic leukemia [ALL], acute myeloid leukemia [AML] or chronic myeloid&#xD;
             leukemia [CML] in blast crisis) are eligible excluding those patients with symptomatic&#xD;
             CNS leukemia, CNS chloromas, or leptomeningeal leukemic involvement&#xD;
&#xD;
          -  Stratum 1: patients must have either measurable or evaluable disease&#xD;
&#xD;
          -  Strata 2 and 3: patients with leukemia must have a &gt; 25% blasts on bone marrow&#xD;
             aspirate to be eligible&#xD;
&#xD;
          -  Patient's current disease state must be one for which there is no known curative&#xD;
             therapy or therapy proven to prolong survival with an acceptable quality of life&#xD;
&#xD;
          -  Karnofsky &gt;= 50% for patients &gt; 16 years of age and Lansky &gt;= 50 for patients =&lt; 16&#xD;
             years of age&#xD;
&#xD;
          -  Patients must have fully recovered from the acute toxic effects of all prior&#xD;
             chemotherapy, immunotherapy, or radiotherapy prior to entering this study&#xD;
&#xD;
               -  Myelosuppressive chemotherapy: must not have received within 3 weeks of&#xD;
                  enrollment onto this study (6 weeks if prior nitrosourea); hydroxyurea may be&#xD;
                  administered prior to study enrollment; in such cases at least 24 hours must have&#xD;
                  elapsed between the last dose of hydroxyurea and the first dose of obatoclax&#xD;
&#xD;
               -  Hematopoietic growth factors: at least 7 days since the completion of therapy&#xD;
                  with a growth factor&#xD;
&#xD;
               -  Biologic (anti-neoplastic agent): at least 7 days since the completion of therapy&#xD;
                  with a biologic agent; for agents that have known adverse events occurring beyond&#xD;
                  7 days after administration, this period must be extended beyond the time during&#xD;
                  which adverse events are known to occur; the duration of this interval must be&#xD;
                  discussed with the study chair&#xD;
&#xD;
               -  Immunotherapy: at least 6 weeks since the completion of any type of&#xD;
                  immunotherapy, e.g. tumor vaccines&#xD;
&#xD;
               -  Monoclonal antibodies: at least 3 half-lives since prior therapy that includes a&#xD;
                  monoclonal antibody&#xD;
&#xD;
               -  Radiation therapy (XRT): &gt;= 2 weeks (wks) for local palliative XRT (small port);&#xD;
                  &gt;= 6 months must have elapsed if prior total-body irradiation (TBI), craniospinal&#xD;
                  XRT or if &gt;= 50% radiation of pelvis; &gt;= 6 wks must have elapsed if other&#xD;
                  substantial bone marrow (BM) radiation&#xD;
&#xD;
               -  Stem cell transplant or rescue without TBI: no evidence of active graft vs. host&#xD;
                  disease and &gt;= 3 months must have elapsed since transplant&#xD;
&#xD;
          -  STRATUM 1: Peripheral absolute neutrophil count (ANC) &gt;= 1000/mm^3&#xD;
&#xD;
          -  STRATUS 1: Platelet count &gt;= 100,000/mm^3 (transfusion independent, defined as not&#xD;
             receiving platelet transfusions within a 7 day period prior to enrollment)&#xD;
&#xD;
          -  STRATUM 1: Hemoglobin &gt;= 8.0 g/dL (may receive red blood cell [RBC] transfusions)&#xD;
&#xD;
          -  STRATA 2 and 3: Platelet count &gt;= 20,000/mm^3 (may receive platelet transfusions)&#xD;
&#xD;
          -  STRATA 2 and 3: Hemoglobin &gt;= 8.0 g/dL (may receive RBC transfusions)&#xD;
&#xD;
          -  Creatinine clearance or radioisotope glomerular filtration rate (GFR) &gt;= 70ml/min/1.73&#xD;
             m^2 OR a serum creatinine based on age/gender as follows:&#xD;
&#xD;
               -  0.5 mg/dL (6 months to &lt; 1 year of age)&#xD;
&#xD;
               -  0.6 mg/dL (1 to &lt; 2 years of age)&#xD;
&#xD;
               -  0.8 mg/dL (2 to &lt; 6 years of age)&#xD;
&#xD;
               -  1 mg/dL (6 to &lt; 10 years of age)&#xD;
&#xD;
               -  1.2 mg/dL (10 to &lt; 13 years of age)&#xD;
&#xD;
               -  1.5 mg/dL (male) or 1.4 mg/dL (female) (13 to &lt; 16 years of age)&#xD;
&#xD;
               -  1.7 mg/dL (male) or 1.4 mg/dL (female) (&gt;= 16 years of age)&#xD;
&#xD;
          -  Bilirubin (sum of conjugated + unconjugated) &gt;= 1.5 x upper limit of normal (ULN) for&#xD;
             age&#xD;
&#xD;
          -  Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) &gt;= 110&#xD;
             U/L; for the purpose of this study, the ULN for SGPT is 45 U/L&#xD;
&#xD;
          -  Serum albumin &gt;= 2 g/dL&#xD;
&#xD;
          -  Shortening fraction of &gt;= 27% by echocardiogram, or ejection fraction of &gt;= 50% by&#xD;
             gated radionuclide study&#xD;
&#xD;
          -  Stable neurological examination for at least 2 weeks prior to study enrollment; no&#xD;
             known &gt; grade 2 unresolved neurological toxicities&#xD;
&#xD;
          -  All patients and/or their parents or legal guardians must sign a written informed&#xD;
             consent; assent, when appropriate, will be obtained according to institutional&#xD;
             guidelines&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breast-feeding women will not be entered on this study; pregnancy tests&#xD;
             must be obtained in girls who are post-menarchal; males or females of reproductive&#xD;
             potential may not participate unless they have agreed to use an effective&#xD;
             contraceptive method&#xD;
&#xD;
          -  Growth factors that support platelet or white cell number or function must not have&#xD;
             been administered within the 7 days prior to enrollment&#xD;
&#xD;
          -  Patients requiring corticosteroids who have not been on a stable or decreasing dose of&#xD;
             corticosteroid for the prior 7 days&#xD;
&#xD;
          -  Patients who are currently receiving another investigational drug are not eligible&#xD;
&#xD;
          -  Patients who are currently receiving other anticancer agents, with the exception of&#xD;
             hydroxyurea, are not eligible; patients with leukemia may receive intrathecal therapy&#xD;
             as outlined&#xD;
&#xD;
          -  Any anti-convulsant medications&#xD;
&#xD;
          -  Patients who have an uncontrolled infection are not eligible&#xD;
&#xD;
          -  Patients who in the opinion of the investigator may not be able to comply with the&#xD;
             safety monitoring requirements of the study are not eligible&#xD;
&#xD;
          -  Patients with a total lifetime cumulative anthracycline dose &gt; 750 mg/m2 (25 mg/kg if&#xD;
             &lt; 1 year) doxorubicin or equivalent at the time of enrollment are not eligible&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Aplenc</last_name>
    <role>Principal Investigator</role>
    <affiliation>COG Phase I Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868-3874</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lurie Children's Hospital-Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Medical Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C S Mott Children's Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Medical Center-Fairview</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Sainte-Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>July 7, 2009</study_first_submitted>
  <study_first_submitted_qc>July 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2009</study_first_posted>
  <last_update_submitted>April 30, 2014</last_update_submitted>
  <last_update_submitted_qc>April 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burkitt Lymphoma</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Immunoblastic</mesh_term>
    <mesh_term>Plasmablastic Lymphoma</mesh_term>
    <mesh_term>Mycosis Fungoides</mesh_term>
    <mesh_term>Sezary Syndrome</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
    <mesh_term>Leukemia, Hairy Cell</mesh_term>
    <mesh_term>Blast Crisis</mesh_term>
    <mesh_term>Lymphomatoid Granulomatosis</mesh_term>
    <mesh_term>Lymphoma, Extranodal NK-T-Cell</mesh_term>
    <mesh_term>Intraocular Lymphoma</mesh_term>
    <mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Dexrazoxane</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Razoxane</mesh_term>
    <mesh_term>Obatoclax</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

